Clinical Trial Update: Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating motolimod with doxorubicin and durvalumab in platinum-resistant recurrent ovarian cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Doxorubicin (doxorubicin)
• Durvalumab (durvalumab)
• motolimod (motolimod)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-09-23